跳至主要内容
临床试验/EUCTR2006-002369-37-GB
EUCTR2006-002369-37-GB进行中(未招募)1 期

ot-to-Lot Consistency Study of the Investigational, Split-virion, Inactivated Influenza Vaccine, Administered by the Intradermal Route in Adults.

Sanofi Pasteur SA0 个研究点目标入组 2,255 人开始时间: 2006年9月20日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
2,255

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1) Aged 18 to 60 years on the day of inclusion
  • 2) Informed consent form signed
  • 3) Able to attend all scheduled visits and to comply with all trial procedures
  • 4) For a woman, inability to bear a child or negative urine pregnancy test at the first visit (V0)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1) Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances
  • 2) Febrile illness (oral temperature = 37.5°C, or rectal equivalent temperature =°38.0°C) on the day of inclusion
  • 3) Participation in another clinical trial in the 4 weeks preceding the trial vaccination
  • 4) Planned participation in another clinical trial during the present trial period
  • 5) Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
  • 6) Unstable chronic illness (defined as illness requiring hospitalization or a clinically significant change in medication in the 12 weeks prior to inclusion) at a stage that could interfere with trial conduct or completion
  • 7) Current abuse of alcohol or drug addiction that may interfere with the subject’s ability to comply with trial procedures
  • 8) Blood or blood-derived products received in the past 3 months
  • 9) Any vaccination in the 4 weeks preceding the trial vaccination
  • 10) Vaccination planned in the 4 weeks following the trial vaccination
  • 11) Previous vaccination against influenza (in the previous 6 months)
  • 12) Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination
  • 13) Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent

研究者

发起方
Sanofi Pasteur SA

相似试验

进行中(未招募)
不适用
ot-to-Lot Consistency Study of the Investigational, Split-virion, Inactivated Influenza Vaccine, Administered by the Intradermal Route in Adults.Vaccination of adults aged 18 to 60 years with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.
EUCTR2006-002369-37-LTSanofi Pasteur SA2,250
招募中
不适用
Comparison of neuromuscular monitorings (TOF-Watch SX versus Philips NMT Module) in patients undergoing rhinoplasty or rhinoseptoplasty.patients undergoing rhinoplasty or rhinoseptoplasty under general anaesthesic
ACTRN12617000625370CHU UCL Namur - Mont-Godinne30
招募中
不适用
Comparison of neuromuscular monitorings (TOF-Watch SX stabilised in the SL TOF tube versus Philips NMT Module stabilised in Philips Hand Adaptor ) in patients undergoing rhinoplasty or rhinoseptoplasty.patients undergoing rhinoplasty or rhinoseptoplasty under general anaesthesic
ACTRN12617001151325CHU UCL Namur - Mont-Godinne30
进行中(未招募)
不适用
Clinical application of continuous cuffless blood pressure monitoring based on optically measured changes in light absorption by blood vesselsHypertension
ISRCTN13366089Department of Hypertension & Vascular Disease, The First Affiliated Hospital, Sun Yat-Sen University300
招募中
不适用
The Study of Reliability and Validity of Pattern Identifications Tool for Cognitive Disorders(PIT-C)Mental and behavioral disorders
KCT0003419Dunsan Korean Medicine Hospital of Daejeon University60